Security record · archived quarter
SMMT
Summit Therapeutics Inc. · Healthcare · Biotechnology
8Tracked holders
—Δ holders
7.47MShares held
$58.27MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 86 | +5 | 84.29M | $1.23B | +8 | −2 |
| Q1 2026 | 82 | +1 | 68.40M | $1.29B | +10 | −10 |
| Q4 2025 | 81 | 0 | 72.69M | $1.27B | +1 | — |
| Q3 2025 | 15 | -1 | 45.07M | $931.26M | +1 | −3 |
| Q2 2025 | 14 | 0 | 38.14M | $811.62M | +1 | −1 |
| Q1 2025 | 11 | +1 | 18.29M | $352.78M | +1 | — |
| Q4 2024 | 10 | +1 | 17.85M | $318.58M | +1 | — |
| Q3 2024 | 8 | 0 | 10.94M | $239.67M | +1 | −1 |
| Q2 2024 | 8 | — | 7.47M | $58.27M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 2.96M | — | $23.12M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.96M | — | $23.12M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 2.04M | — | $15.93M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 2.04M | — | $15.93M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Millennium Management ✦ | 1.94M | — | $15.15M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 268.15K | — | $2.09M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 268.15K | — | $2.09M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Arrowstreet Capital ✦ | 141.68K | — | $1.10M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 62.11K | — | $484,490 | 0.0% | n/c | 1 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 62.11K | — | $484,490 | 0.0% | n/c | 1 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 29.70K | — | $231,660 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Gotham Asset Management ✦ | 19.50K | — | $152,100 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 223 holders, 118.88M shares, $2.10B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API